Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16951652 | 0.89 | TSHR (0.57) | ALOX5SMN1; SMN2LMNAMEN1HTT | |
| SCHEMBL16951649 | 0.88 | ALOX5 (0.43) | ALOX5CYP3A4SMN1; SMN2LMNAMEN1 | |
| SCHEMBL16958760 | 0.88 | ALOX5 (0.46) | ALOX5CYP3A4SMN1; SMN2LMNAMEN1 | |
| SCHEMBL16955456 | 0.85 | CYP4F2 (0.58) | ALOX5SMN1; SMN2LMNAMEN1HTT | |
| SCHEMBL16955454 | 0.85 | LMNA (0.44) | ALOX5CYP3A4SMN1; SMN2CYP19A1LMNA | |
| SCHEMBL5631287 | 0.84 | P2RX1 (0.40) | ALOX5CYP3A4LMNATSHRMAPT | |
| SCHEMBL16959077 | 0.84 | LMNA (0.43) | ALOX5CYP3A4SMN1; SMN2CYP19A1LMNA | |
| SCHEMBL16959075 | 0.84 | VCAM1 (0.39) | ALOX5CYP3A4SMN1; SMN2LMNAMEN1 | |
| SCHEMBL8930392 | 0.84 | POLB (0.44) | ALOX5CYP3A4SMN1; SMN2LMNAMEN1 | |
| SCHEMBL16958761 | 0.82 | LMNA (0.40) | ALOX5SMN1; SMN2LMNAMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
| EP-1590005-B1 | CONJUGATES OF ENANTIOMER-PURE (4S,8S)- AND (4R,8R)-4-P-BENZYL-8-METHYL-3,6,9-TRIAZA- SP 3 /SP N, SP 6 /SP N, SP 9 /SP N-TRICARBOXYMETHYL-1,11-UNDECANOIC ACID WITH BIOMOLECULES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS | Bayer Pharma AG (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
| EP-1409024-B1 | MACROCYCLIC METAL COMPLEXES AND USE THEREOF FOR PRODUCTION OF CONJUGATES WITH BIOMOLECULES | BAYER SCHERING PHARMA AG (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-7208140-B2 | Trimeric macrocyclic substituted benzene derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-24 | — | — | US | disclosed |
| EP-1590317-B1 | ENANTIOMER-PURE (4S,8S)- AND (4R, 8R)-4-P-NITROBENZYL-8-METHYL-3, 6, 9-TRIAZA- SP 3 /sp N, SP 6 /SP N, SP 9 /SP N-TRICARBOXYMETHYL-1, 11-UNDECANOIC ACID AND DERIVATIVES THEREOF, METHOD FOR PRODUCING THEM, AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | ALOX5 4670/4885CYP3A4 3785/4885SMN1; SMN2 3189/4885 |
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | C5, C3AR1, SPR | ALOX5 940/4885CYP3A4 1500/4885SMN1; SMN2 3717/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | ALOX5 4636/4885CYP3A4 3115/4885SMN1; SMN2 2812/4885 |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | ALOX5 349/4885CYP3A4 15/4885SMN1; SMN2 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.